

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Under the Patent Reform Act of 2013, no person may prepare or file a patent application on behalf of an inventor unless the inventor is a U.S. citizen or a U.S. permanent resident.

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 1 of 7

Attorney Docket No: 295.061US4

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
DB	4,237,224	12/02/1980	Cohen et al.
	4,399,216	08/16/1983	Axel et al.
	4,468,464	08/28/1984	Cohen et al.
	4,634,665	01/06/1987	Axel et al.
	4,656,134	04/07/1987	Ringold
	4,740,470	04/26/1988	Cohen et al.
	4,816,397	03/28/1989	Boss et al.
	4,816,567	03/28/1989	Cabilly et al.
	4,870,023	09/26/1989	Fraser et al.
	4,879,236	11/07/1989	Smith et al.
	4,946,778	08/07/1990	Ladner et al.
	4,975,369	12/04/1990	Beavers et al.
	5,015,580	05/14/1991	Christou et al.
	5,041,379	08/20/1991	Fraser et al.
	5,071,748	12/10/1991	Miller
	5,077,214	12/31/1991	Guarino et al.
	5,084,396	01/28/1992	Morgan et al.
	5,091,513	02/25/1992	Huston et al.
	5,110,729	05/05/1992	Maeda et al.
	5,120,657	06/09/1992	McCabe et al.
	5,122,458	06/16/1992	Post et al.
	5,132,405	07/21/1992	Huston et al.
	5,147,788	09/15/1992	Page et al.
	5,149,655	09/22/1992	McCabe et al.
	5,155,037	10/13/1992	Summers
	5,162,222	11/10/1992	Guarino et al.
	5,169,784	12/08/1992	Summers et al.
	5,169,939	12/08/1992	Geffer et al.
	5,179,007	01/12/1993	Jarvis et al.
	5,179,017	01/12/1993	Axel et al.
	5,185,254	02/09/1993	Linnenbach,
	5,202,422	04/13/1993	Hiatt et al.
	5,225,539	07/06/1993	Winter
	5,260,203	11/09/1993	Ladner et al.
	5,266,314	11/30/1993	Maeda
	5,304,489	04/19/1994	Rosen
	5,322,774	06/21/1994	Peakman et al.
	5,348,886	09/20/1994	Lee et al.
	5,348,887	09/20/1994	Bumol et al.
DB	5,349,053	09/20/1994	Landolfi

EXAMINER

/David Blanchard/


DATE CONSIDERED 01/19/2007

Substitute Disclosure Statement Form (PTO-1449)  
EXAMINER: Initial references considered, whether or not citation is in compliance with MPEP 609. Draw line through citation if not in compliance and not considered. (Include copy of this form with next communication to applicant.) Applicant's unique citation designation number (optional) \* Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Under the Patent & Trademark Act of 1980, no person is required to respond to a notice of information disclosure unless it results in a new or amended claim.

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 2 of 7

Attorney Docket No: 295.061US4

## **US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
DB	5,385,839	01/31/1995	Stinski
↓	5,405,779	04/11/1995	McCabe et al.
	5,413,923	05/09/1995	Kucheralapati et al.
	5,422,281	06/06/1995	Harris et al.
	5,434,340	07/18/1995	Krimpenfort et al.
	5,443,953	08/22/1995	Hansen et al.
	5,464,764	11/07/1995	Capecci et al.
	5,476,786	12/19/1995	Huston
	5,487,992	01/30/1996	Capecchi et al.
	5,503,998	04/02/1996	Christou et al.
	5,506,125	04/09/1996	McCabe et al.
	5,525,510	06/11/1996	McCabe et al.
	5,530,101	06/25/1996	Queen et al.
	5,545,403	08/13/1996	Page
	5,545,404	08/13/1996	Page
	5,545,405	08/13/1996	Page
	5,545,806	08/13/1996	Lonberg et al.
	5,569,825	10/29/1996	Lonberg et al.
	5,578,287	11/26/1996	Theodore et al.
	5,584,807	12/17/1996	McCabe
	5,585,089	12/17/1996	Queen et al.
	5,585,097	12/17/1996	Bolt et al.
↓	5,624,821	04/29/1997	Winter et al.
	5,639,947	06/17/1997	Hiatt et al.
DB	5,869,620	02/09/1999	Whitlow et al.

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	T*
DB	CA 1316852	04/27/1993	
↓	EP 0 045 809	08/19/1987	
	EP 0 120 694	07/21/1993	
	EP 0 125 023	06/05/1991	
	EP 0 173 552	03/05/1986	
	EP 0 239 400	09/30/1987	
	EP 0 260 148	03/16/1988	
	EP 0 319 206	06/07/1989	
	EP 0 328 404	09/29/1993	
↓	EP 0 338 841	10/25/1989	
	EP 0 393 045	03/29/1995	
DB	EP 0 411 893	02/06/1991	

EXAMINER

/David Blanchard/

DATE CONSIDERED 01/19/2007

Substitute Disclosure Statement Form (PTO-1449)  
\* EXAMINER: Initial of reference considered, whether or not citation is in accordance with MPEP 609. Draw line through citation if not in accordance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Use as many sheets as necessary.

Approved for use through 12/31/2002. Obsolete.  
US Patent & Trademark Office, 400 ...  
Under the Payment Reduction Act of 1993, no payment is due, and no refund is due, for any fee paid for this form.

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 3 of 7

Attorney Docket No: 295.061US4

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	T
DB	EP 0 451 216	01/24/1996	
	EP 0 460 167	10/11/1995	
	EP 0 520 962	12/30/1992	
	EP 0 578 515	01/12/1994	
	EP 0 592 106	04/13/1994	
	EP 0 614 982	09/14/1994	
	EP 0 682 040	11/15/1995	
	EP 0 699 755	03/06/1996	
	GB 2188638	10/07/1987	
	WO 84/03712	09/27/1984	
	WO 86/01533	03/13/1986	
	WO 86/02097	04/10/1986	
	WO 86/05807	10/09/1986	
	WO 87/04462	07/30/1987	
	WO 88/01649	03/10/1988	
	WO 88/06630	09/07/1988	
	WO 89/01036	02/09/1989	
	WO 89/09825	10/19/1989	
	WO 89/10404	11/02/1989	
	WO 90/04036	04/19/1990	
	WO 90/10457	09/20/1990	
	WO 91/06320	05/16/1991	
	WO 91/06657	05/16/1991	
	WO 91/09967	07/11/1991	
	WO 92/04381	03/19/1992	
	WO 92/11018	07/09/1992	
	WO 92/15683	09/17/1992	
	WO 92/22653	12/23/1992	
	WO 93/08300	04/29/1993	
	WO 93/11238	06/10/1993	
	WO 93/12246	06/24/1993	
	WO 93/16185	08/19/1993	
	WO 93/17105	09/02/1993	
	WO 93/22332	11/11/1993	
	WO 93/22442	11/11/1993	
	WO 93/23537	11/25/1993	
	WO 93/25240	12/23/1993	
	WO 94/04679	03/03/1994	
	WO 94/09131	04/28/1994	
	WO 94/12625	06/09/1994	
DB	WO 94/22902	10/13/1994	

EXAMINER

/David Blanchard/

DATE CONSIDERED 01/19/2007

Substitute Disclosure Statement Form (PTO-1449)  
\* EXAMINER (check if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.) Applicant's unique citation designation number (optional) Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 4 of 7

Attorney Docket No: 295.061US4

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	T <sup>2</sup>
DB	WO 94/29451	12/22/1994	
↓	WO 95/08577	03/30/1995	
	WO 95/15335	06/08/1995	
	WO 95/15341	06/08/1995	
	WO 95/15769	06/15/1995	
	WO 95/20672	08/03/1995	WPI Acc. No. 95-275457
	WO 95/25167	09/21/1995	
↓	WO 96/05228	02/22/1996	
	WO 96/11013	04/18/1996	
DB	WO 96/27011	09/06/1996	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DB	ABRAHAM, "The Influence of Periodate Oxidation on Monoclonal Antibody Avidity and Immunoreactivity", <u>Journal of Immunological Methods</u> , 144, 77-86 (1991).
	BETTER, "Escherichia Coli Secretion of an Active Chimeric Antibody FragmentT", <u>Science</u> , 240, 1041-1043 (1988).
	BREKKE et al., "The Structural Requirements for Complement Activation by IgC: Does it Hinge on the Hinge?", <u>Immunology Today</u> , 16, 85-90 (1995).
	BRUGGEMANN et al., "Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies", <u>J. Exp. Med.</u> , 166, 1351-1361 (1987).
	CANFIELD et al., "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the Ch2 Domain and is Modulated by the Hinge Region", <u>J. Exp. Med.</u> , 173, 1483-1491 (1991).
	CARON et al., "Biological and Immunological Features of Humanized M195 (anti-CD33) Monoclonal Antibodies", <u>Cancer Research</u> , 52, 6761-6767 (1992).
	CO et al., "Genetically Engineered Deglycosylation of the Variable Domain Increases the Affinity of an Anti-CD 33 Monoclonal Antibody", <u>Molecular Immunology</u> , 30, 1361-1367 (1993).
	COUTO et al., "Cloning of cDNAs Encoding the Variable Domains of Antibody KC4G3 and Construction of a Chimeric Antibody", <u>Hybridoma</u> , 12, 485-489 (1993).
	DAVIS et al., "Glycosylation Governs the Binding of Anti-peptide Antibodies to Regions of Hypervariable Amino Acid Sequence Within Recombinant GP120 of Human Immunodeficiency Virus Type 1", <u>Journal of General Virology</u> , 71, 2889-2898 (1990).
	DORAI et al., "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Functions", <u>Hybridoma</u> , 10, 211-217 (1991).
	DUNCAN et al., "The Binding Site for C1q on IgG", <u>Nature</u> , 332, 738-740 (1988).
↓	DWEK et al., "Glycobiology: The Function of Sugar in the IgG Molecule", <u>The Journal of Anatomy</u> , 187, 279-292 (1995).
DB	ENDO et al., "Glycosylation of the Variable Region of Immunoglobulin G Site Specific Maturation of the Sugar Chains", <u>Molecular Immunology</u> , 32, 931-940 (1995).

EXAMINER

/David Blanchard/

DATE CONSIDERED

01/19/2007

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Under the Patent Act of 1952, no person is required to respond to a notice or information unless it contains a valid OIA computer number.

Complete if Known	<b>Application Number</b>	10/787,067
	<b>Filing Date</b>	February 25, 2004
	<b>First Named Inventor</b>	Graves, Scott
	<b>Group Art Unit</b>	1642
	<b>Examiner Name</b>	Unknown
Sheet 5 of 7		Attorney Docket No: 295.061US4

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DB	GEYSEN et al., "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid", <u>PNAS</u> , 81, 3998-4002 (1984).
	GOSHORN, "Preclinical Development of huNR-LU-10, a Humanized Antibody for Tumor Targeting", <u>Immunotechnology</u> , 2, 300 (1996).
	GREENMAN et al., "The Use of Intracellular Single-Chain Antibody Fragments to Inhibit Specifically the Expression of Cell Surface Molecules", <u>Journal of Immunological Methods</u> , 194, 169-180 (1996).
	GREENSPAN et al., "Defining Epitopes: It's Not as Easy as it Seems", <u>Nature Biotechnology</u> , 17, 936-937 (1999).
	HAND et al., "Comparative Biological Properties of a Recombinant Chimeric Anti-Carcinoma mAb and a Recombinant Aglycosylated Variant", <u>Cancer Immunology Immunotherapy</u> , 35, 165-174 (1992).
	HELFRICH et al., "Epitope Mapping of SCLC-Cluster-2 Mabs and Generation of Antibodies Directed Against New EGP-2 Epitopes", <u>Int. J. Cancer Suppl.</u> , 8, 64-69 (1994).
	HERLYN et al., "CO 17-1A and Related Monoclonal Antibodies: Their Production and Characterization", <u>Hybridoma</u> , 5(Suppl. 1), S3-S10 (1986).
	HEYMAN et al., "Carbohydrate Chains on IgG2b: A Requirement for Efficient Feedback Immunosuppression", <u>The Journal of Immunology</u> , 134, 4018-4023 (1985).
	HOUBA et al., "Improved Characteristics of a Human B-Glucuronidase-Antibody Conjugate After Decycosylation for Use in Antibody-Directed Enzyme Prodrug Therapy", <u>Bioconjugate Chem.</u> , 7, 606-611 (1996).
	KABAT, "The Structural Basis of Antibody Complementarity", <u>Adv Protein Chem</u> , 32, 1-75 (1978).
	LEIJ et al., "SCLC-Cluster-2 Antibodies Detect the Pancarcinoma/Epithelial Glycoprotein EGP-2", <u>International Journal of Cancer, Supplement</u> , 8, 60-63 (1994).
	LEUNG et al., "Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific, Leukemia/Lymphoma Antibody LL2", <u>Molecular Immunology</u> , 32, 1413-1427 (1995).
	LITVINOV et al., "Ep-CAM: A Human Epithelial Antigen Is a Homophilic Cell-Cell Adhesion Molecule", <u>The Journal of Cell Biology</u> , 125, 437-446 (1994).
	LUND et al., "Control of IgG/Fc Glycosylation: A Comparison of Oligosaccharides From Chimeric Human/Mouse and Mouse Subclass Immunoglobulin", <u>Molecular Immunology</u> , 30, 741-748 (1993).
	MA et al., "Immunotherapeutic Potential of Antibodies Produced in Plants", <u>Trends in Biotechnology</u> , 13, 522-527 (1995).
	MCCLOSKEY et al., "Human Constant Regions Influence the Antibody Binding Characteristics of Mouse-Human Chimeric IgG Subclasses", <u>Immunology</u> , 88, 169-173 (1996).
	MORGAN et al., "The N-Terminal End of the CH2 Domain of Chimeric Human IgG: Anti-HLA-DR is Necessary for C1q, FcγR1 and FcγR1 and FcγRIII Binding", <u>Immunology</u> , 86, 319-324 (1995).
↓	MORRISON et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains", <u>PNAS</u> , 81, 6851-6855 (1984).
DB	MORRISON et al., "In vitro Antibodies: Strategies for Production and Application", <u>Annu. Rev. Immunol.</u> , 10, 239-265 (1992).

EXAMINER

/David Blanchard/

DATE CONSIDERED

01/19/2007

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Approved for use through 10/31/2002. OIG 03-0031  
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it displays a valid OIG number.

Sheet 6 of 7

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Attorney Docket No: 295.061US4

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DB	MURAOKA et al., "Structural Requirements for IgM Assembly and Cytolytic Activity", <u>The Journal of Immunology</u> , 142, 695-701 (1989).
	NISHIMURA et al., "Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen", <u>Cancer Research</u> , 47, 999-1005 (1987).
	NOSE et al., "Biological Significance of Carbohydrate Chains on Monoclonal Antibodies", <u>PNAS</u> , 80, 6632-6636 (1983).
	PEAKE et al., "Does Non-Enzymatic Glycosylation Affect Complement Function in Diabetes?", <u>Diabetes Research</u> , 11, 109-114 (1989).
	PLUCKTHUN et al., "New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments", <u>Immunotechnology</u> , 3, 83-105 (1997).
	POUND et al., "Aglycosylated Chimaeric Human IgG3 Can Trigger the Human Phagocyte Respiratory Burst", <u>Molecular Immunology</u> , 30, 233-241 (1993).
	RODWELL et al., "Engineering Monoclonal Antibodies", <u>Nature</u> , 342, 99-100 (1989).
	SARMAY et al., "Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fcγ Receptor", <u>Molecular Immunology</u> , 29, 633-639 (1992).
	STRNAD et al., "Molecular Cloning and Characterization of a Human Adenocarcinoma/Epithelial Cell Surface Antigen Complementary DNA", <u>Cancer Research</u> , 49, 314-317 (1989).
	SZALA et al., "Molecular Cloning of cDNA for the Carcinoma-Associated Antigen GA733-2", <u>PNAS</u> , 87, 3542-3546 (1990).
	TACHIBANA et al., "Identification of Hybrid-Type Carbohydrate Chains on the Light Chain of Human Monoclonal Antibody Specific to Lung Adenocarcinoma", <u>Biochimica et Biophysica Acta</u> , 1182, 257-263 (1993).
	TAMS et al., "Mild Chemical Deglycosylation of Horseradish Peroxidase Yields a Fully Active, Homogeneous Enzyme", <u>Analytical Biochemistry</u> , 228, 48-55 (1995).
	TAO et al., "Studies of Aglycosylated Chimeric Mouse-Human IgG - Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region", <u>The Journal of Immunology</u> , 143, 2595-2601 (1989).
	TAO et al., "The Differential Ability of Human IgG1 AND IgG4 to Activate Complement is Determined by the COOH-Terminal Sequence of the Ch2 Domain", <u>J. Exp. Med.</u> , 173, 1025-1028 (1991).
	TAYLOR et al., "Altered Glycosylation and Selected Mutation in Recombinant Human Complement Component C9: Effects on Haemolytic Activity", <u>Immunology</u> , 83, 501-506 (1994).
	VERHOEYEN et al., "Engineering of Antibodies", <u>BioAssays</u> , 8, 74-78 (1988).
	WEIDEN et al., "Rhenium-186-Labeled Chimeric Antibody NR-LU-13: Pharmacokinetics, Biodistribution and Immunogenicity Relative to Murine Analog NR-LU-10", <u>J Nucl Med</u> , 34, 2111-2119 (1993).
✓	WINKELHAKE et al., "Effects of pH Treatments and Deglycosylation of Rabbit Immunoglobulin G on the Binding of C1q", <u>The Journal of Biological Chemistry</u> , 255, 2822-2828 (1980).
DB	WOOF et al., "The Role of Glycosylation in Antibody Effector Function", <u>GlycoNews Second</u> , 94, 1-4 (1994).

EXAMINER

/David Blanchard/

DATE CONSIDERED

01/19/2007

\* EXAMINER: Initial of reference considered, whether or not citation is in accordance with MPEP 609. Draw line through citation if not in accordance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Under the Patent and Trademark Act of 1952, no person is required to respond to a written communication unless it contains a valid mailing address.

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 7 of 7

Attorney Docket No: 295.061US4

## **OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DB	XIA et al., "Efficient Complement-Mediated Lysis of Cells Containing the Campath-1 (CDw52) Antigen", <u>Molecular Immunology</u> , 30, 1089-1096 (1993).
DB	XIA et al., "Structure of the CAMPATH-1 Antigen, a Glycosylphosphatidylinositol-Anchored Glycoprotein Which is an Exceptionally Good Target for Complement Lysis", <u>Biochemical Journal</u> , 293, 633-640 (1993).
DB	YOSHIDA et al., "Mutants of Dictyostelium Discoideum With Altered Carbohydrate Moieties of Contact Site A", <u>Cell Structure and Function</u> , 16, 383-390 (1991).

EXAMINER

/David Blanchard/

DATE CONSIDERED

01/19/2007

Substitute Disclosure Statement Form (PTO-1448)

\* EXAMINER: Initial if reference considered, whether or not citation is in compliance with MPEP 609. Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known****Application Number** 10/787,067**Filing Date** February 25, 2004**First Named Inventor** Graves, Scott**Group Art Unit** 1642**Examiner Name** Unknown**Attorney Docket No:** 295.061US4**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
DB	2003/0119078	06/26/2003	Graves et al.	01/24/2002
DB	6,358,710	03/19/2002	Graves et al.	06/09/1997

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	T <sup>2</sup>
DB	EP 0 173 177	03/05/1986	Abstract Only

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DB	ALBERTS et al., "Molecular Biology of the Cell", Third Edition, Garland Press, New York, NY, 606-608 (1994).
	BENVENUTO et al., "Phytoantibodies: a general vector for the expression of immunoglobulin domains in transgenic plants", <u>Plant Molecular Biology</u> , 17, 865-874 (1991).
	BHATIA et al., "Protein glycosylation: Implications for in vivo functions and therapeutic applications", <u>Advances in Biochemical Engineering / Biotechnology</u> , 64, 155-201 (1999).
	BOLT et al., "The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties", <u>Eur. J. Immunol.</u> , 23, 403-411 (1993).
	BUCKEL et al., "Cloning and nucleotide sequence of heavy- and light-chain cDNAs from a creatine-kinase-specific monoclonal antibody", <u>Gene</u> , 51, 13-19 (1987).
	CUELLO et al., "Detection of substance P in the central nervous system by a monoclonal antibody", <u>PNAS</u> , 76, 3532-3536 (1979).
	DE NEVE et al., "Assembly of an antibody and its derived antibody fragment in Nicotiana and Arabidopsis", <u>Transgenic Research</u> , 2, 227-237 (1993).
	DURING et al., "Synthesis and self-assembly of a functional monoclonal antibody in transgenic Nicotiana tabacum", <u>Plant Molecular Biology</u> , 15, 281-293 (1990).
	FIREK et al., "Secretion of a functional single-chain Fv protein in transgenic tobacco plants and cell suspension cultures", <u>Plant Molecular Biology</u> , 23, 861-870 (1993).
	GOMEZ et al., "Complementation of an Arabidopsis thaliana mutant that lacks complex asparagine-linked glycans with the human cDNA encoding N-acetylglucosaminyltransferase I.", <u>PNAS</u> , 91, 1829-1833 (1994).
	HAN et al., "Possible Relationship Between Coding Recognition Amino Acid Sequence Motif or Residue(s) and Post-Translational Chemical Modification of Proteins", <u>Int. J. Biochem.</u> , 24, 1349-1363 (1992).
	HART et al., "Chapter 10. O-Linked N-Acetylglucosamine: The "Yin-Yang" of Ser/Thr Phosphorylation?", In: <u>Glycoimmunology</u> , Plenum Press, New York, 115-123 (1995).
↓	HEIN et al., "Evaluation of immunoglobulins from plant cells", <u>Biotechnol. Prog.</u> , 7, 455-461 (1991).
DB	HESSE et al., "Molecular Cloning and Structural Analysis of a Gene from Zea Mays (L.) Coding for a Putative Receptor for the Plant Hormone Auxin", <u>The EMBO Journal</u> , 8, 2453-2461 (1989).

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language Translation is attached



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/787,067
<b>Filing Date</b>	February 25, 2004
<b>First Named Inventor</b>	Graves, Scott
<b>Group Art Unit</b>	1642
<b>Examiner Name</b>	Unknown

Sheet 2 of 3

Attorney Docket No: 295.061US4

DB	HIATT et al., "Production of antibodies in transgenic plants", <u>Nature</u> , 342, 76-78 (1989).
	HOUNSELL et al., "O-linked protein glycosylation structure and function", <u>Glycoconjugate Journal</u> , 13, 19-26 (1996).
	HUGHES et al., "Capillary Electrophoretic Examination of Underivatized O-Linked and N-Linked Oligosaccharide Mixtures and Immunoglobulin G Antibody-Released Oligosaccharide Libraries", <u>Journal of Chromatography B</u> , 657, 315-326 (1994).
	ISAACS et al., "Therapy with Monoclonal Antibodies - An in vivo Model for the Assessment of Therapeutic Potential", <u>The Journal of Immunology</u> , 148, 3062-3071 (1992).
	JEFFERIS et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcγR)", <u>Molecular Immunology</u> , 27, 1237-1240 (1990).
	JENKINS et al., "Glycosylation of recombinant proteins: problems and prospects", <u>Enzyme Microb. Technol.</u> , 16, 354-364 (1994).
	JONES et al., "Replacing the Complementarity-Determining Regions in a Human Antibody With Those of a Mouse", <u>Nature</u> , 321, 522-525 (1986).
	KABIR et al., "The Binding of Jacalin With Rabbit Immunoglobulin G", <u>Immunological Investigations</u> , 24, 725-735 (1995).
	KUMPEL et al., "Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity", <u>Hum Antibodies Hybridomas</u> , 5, 143-151 (1994).
	KUWANO et al., "Glycosylation mutations of serine/threonine-linked oligosaccharides in low-density lipoprotein receptor: indispensable roles of O-glycosylation", <u>Journal of Cell Science</u> , 98, 131-134 (1991).
	LARRICK et al., "Recombinant antibodies", <u>Hum. Antibod. Hybridomas</u> , 2, 172-189 (1991).
	LEBECQUE et al., "Immunologic Characterization of Monoclonal Antibodies that Modular Human IgE Binding to the Major Birch Pollen Allergen Bet v1", <u>The Journal of Allergy and Clinical Immunology</u> , 99, 15 pages (1997).
	LECOMMANDEUR et al., "Glycan Research on Barley, Maize, Oats, and Sorghum Grain Alpha-Amylases: Comparison with Rice alpha-Amylase", <u>Archives of Biochemistry and Biophysics</u> , 278, 245-250 (1990).
	LEIBIGER et al., "Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding", <u>Biochemical Journal</u> , 338, 529-538 (1999).
	LEROUGE et al., "N-Glycosylation of Recombinant Pharmaceutical Glycoproteins Produced in Transgenic Plants: Towards an Humanisation of Plant N-Glycans", <u>Current Pharmaceutical Biotechnology</u> , 1, 347-354 (2000).
	MA et al., "Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants", <u>Eur. J. Immunol.</u> , 24, 131-138 (1994).
	MA et al., "Generation and assembly of secretory antibodies in plants", <u>Science</u> , 268, 716-719 (1995).
↓	MESA et al., "Interferon-gamma receptor extracellular domain-IgG fusion protein produced in Chinese hamster ovary cells as mixture of glycoforms", <u>Journal of Interferon and Cytokine Research</u> , 15, 309-315 (1995).
DB	OWEN et al., "Synthesis of a functional anti-phytochrome single-chain Fv protein in transgenic tobacco", <u>Biotechnology</u> , 10, 790-794 (1992).

EXAMINER

/David Blanchard/

DATE CONSIDERED

01/19/2007

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1642
Examiner Name	Unknown

Sheet 3 of 3

Attorney Docket No: 295.061US4

DB	ROUTLEDGE et al., "A humanized monovalent CD3 antibody which can activate homologous complement", <u>Eur. J. Immunol.</u> , <b>21</b> , 2717-2725 (1991).
	ROUTLEDGE et al., "The Effect of Aglycosylation on the Immunogenicity of a Humanized Therapeutic CD3 Monoclonal Antibody", <u>Transplantation</u> , <b>60</b> , 847-853 (1995).
	RUSSELL, "Feasibility of antibody production in plants for human therapeutic use", <u>Curr Top Microbiol Immunol.</u> , <b>240</b> , 119-138 (1999).
	STOGER et al., "Plantibodies: applications, advantages and bottlenecks", <u>Current Opinion in Biotechnology</u> , <b>13</b> , 161-166 (2002).
	SWAIN, "Antibodies in plants", <u>TIBTECH</u> , <b>9</b> , 107-109 (1991).
	TAKAHASHI et al., "Structure of human immunoglobulin gamma genes: implications for evolution of a gene family", <u>Cell</u> , <b>29</b> , 671-679 (1982).
	TALWAR, "Fertility Regulating and Immunotherapeutic Vaccines Reaching Human Trials Stage", <u>Human Reproduction Update</u> , <b>3</b> , 301-310 (1997).
	TANIMOTO et al., "Restricted Expression of an Early Myeloid and Monocytic Cell Surface Antigen Defined by Monoclonal Antibody M195", <u>Leukemia</u> , <b>3</b> , 339-348 (1989).
	TAVLADORAKI et al., "Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack", <u>Nature</u> , <b>366</b> , 469-472 (1993).
	VAN ENGELEN et al., "Coordinate Expression of Antibody Subunit Genes Yields High Levels of Functional Antibodies in Roots of Transgenic Tobacco", <u>Plant Molecular Biology</u> , <b>26</b> , 1701-1710 (1994).
	VERHOEYEN et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", <u>Science</u> , <b>239</b> , 1534-1536 (1988).
	VON SCHAEWEN et al., "Isolation of a mutant Arabidopsis plant that lacks N-acetyl glucosaminyl transferase I and is unable to synthesize Golgi-modified complex N-linked glycans", <u>Plant Physiol.</u> , <b>102</b> , 1109-1118 (1993).
	WILSON, "Glycosylation of proteins in plants and invertebrates", <u>Current Opinion in Structural Biology</u> , <b>12</b> , 569-577 (2002).
	WORMALD et al., "Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides", <u>Biochemistry</u> , <b>36</b> , 1370-1380 (1997).
	WRIGHT et al., "Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1", <u>J. Exp. Med.</u> , <b>180</b> , 1087-1096 (1994).
DB	YOUINGS et al., "Site-Specific Glycosylation of Human Immunoglobulin G is Altered in Four Rheumatoid Arthritis Patients", <u>Biochem. J.</u> , <b>314</b> , 621-630 (1996).

EXAMINER

/David Blanchard/

DATE CONSIDERED

01/19/2007

Substitute Disclosure Statement Form (PTO-1449)


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number 10/787,067

Filing Date February 25, 2004

First Named Inventor Graves, Scott

Group Art Unit 1642

Examiner Name Unknown

Attorney Docket No: 295.061US4

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
DB	US-2005/0100545A1	05/12/2005	Graves, S. S., et al.	07/31/2003

EXAMINER


/David Blanchard/

DATE CONSIDERED

01/19/2007

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/787,067
Filing Date	February 25, 2004
First Named Inventor	Graves, Scott
Group Art Unit	1643
Examiner Name	Blanchard, David

Sheet 1 of 1

Attorney Docket No: 295.061US4

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
DB	US-5,714,350	02/03/1998	Co, M. S., et al.	01/13/1995
DB	US-5,856,106	01/05/1999	Awwad, M. G., et al.	11/01/1995

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
DB	WO-93/19196A1	09/30/1993	Bolt, S. L., et al.	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB		GOLDENBERG, D. M., "New Developments in Monoclonal Antibodies for Cancer Detection and Therapy", <u>CA: A Cancer Journal for Clinicians</u> , 44(1), (1994), 43-64	
DB		WEITZHANDLER, M., et al., "Analysis of Carbohydrates on IgG Preparations", <u>Journal of Pharmaceutical Sciences</u> 83(12), (December, 1994), 1670-1675	

EXAMINER

/David Blanchard/

DATE CONSIDERED

01/19/2007

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant to place a check mark here if English language Translation is attached